Unravelling the Antifibrinolytic Mechanism of Action of the 1,2,3-Triazole Derivatives
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25137002 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Yvette Rabadà und 7 weiteren Autor:innen. Beteiligte Einrichtung: IQS School of Engineering, Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain. Hauptthemen laut MEDLINE: Triazoles, Antifibrinolytic Agents, Tranexamic Acid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish Ministerio de Economía, Industria y Competitividad, “La Caixa” Foundation, Fundació Empreses IQS and MIT-Spain Seed Fund.
Abstract (Originalsprache)
A new family of antifibrinolytic drugs has been recently discovered, combining a triazole moiety, an oxadiazolone, and a terminal amine. Two of the molecules of this family have shown activity that is greater than or similar to that of tranexamic acid (TXA), the current antifibrinolytic gold standard, which has been associated with several side effects and whose use is limited in patients with renal impairment. The aim of this work was to thoroughly examine the mechanism of action of the two ideal candidates of the 1,2,3-triazole family and compare them with TXA, to identify an antifibrinolytic alternative active at lower dosages. Specifically, the antifibrinolytic activity of the two compounds (1 and 5) and TXA was assessed in fibrinolytic isolated systems and in whole blood. Results revealed that despite having an activity pathway comparable to that of TXA, both compounds showed greater activity in blood. These differences could be attributed to a more stable ligand–target binding to the pocket of plasminogen for compounds 1 and 5, as suggested by molecular dynamic simulations. This work presents further evidence of the antifibrinolytic activity of the two best candidates of the 1,2,3-triazole family and paves the way for incorporating these molecules as new antifibrinolytic therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IQS School of Engineering, Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain.
- Institute of Medical Engineering and Science, Massachusetts Institute of Technology, 77 Massachusetts Ave., Cambridge, MA 02139, USA.
- Laboratory of Biochemistry, Institut Químic de Sarrià, Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain.
- Alxerion Biotech, 245 First St, Riverview II, 18th Floor, Cambridge, MA 02142, USA.
- Grup d'Enginyeria de Materials, Institut Químic de Sarrià, Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain.
ORCID-Profile: Xevi Biarnés, David Sánchez-García, Jordi Martorell
Förderung
- Spanish Ministerio de Economía, Industria y Competitividad
- “La Caixa” Foundation
- Fundació Empreses IQS and MIT-Spain Seed Fund
Zitieren
APA
Rabadà, Y., Bosch-Sanz, O., Biarnés, X., Pedreño, J., Caveda, L., Sánchez-García, D., Martorell, J., & Balcells, M. (2024). Unravelling the Antifibrinolytic Mechanism of Action of the 1,2,3-Triazole Derivatives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137002
Vancouver
Rabadà Y, Bosch-Sanz O, Biarnés X, Pedreño J, Caveda L, Sánchez-García D, et al. Unravelling the Antifibrinolytic Mechanism of Action of the 1,2,3-Triazole Derivatives. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25137002
BibTeX
@article{Rabad2024,
author = {Rabadà, Yvette and Bosch-Sanz, Oriol and Biarnés, Xevi and Pedreño, Javier and Caveda, Luis and Sánchez-García, David and Martorell, Jordi and Balcells, Mercedes},
title = {Unravelling the Antifibrinolytic Mechanism of Action of the 1,2,3-Triazole Derivatives},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25137002}
}
EUVIMED